Evidence map›Paper›PMID 27925785›Full record

ArticleAnnals of the American Thoracic Society2016

Accelerating Scientific Advancement for Pediatric Rare Lung Disease Research. Report from a National Institutes of Health-NHLBI Workshop, September 3 and 4, 2015.

Lisa R Young, Bruce C Trapnell, Kenneth D Mandl, Daniel T Swarr, Jennifer A Wambach, Carol J Blaisdell

Abstract read
In one paragraph

Article in Annals of the American Thoracic Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Observational
  2. Article
  3. Pulmonary Aptamer Signatures in Children's Interstitial and Diffuse Lung Disease.American journal of respiratory and critical care medicine · 2019
    Article
  4. Identifying Biomarkers in Pediatric Rare Lung Disease. chILD Grows Up.American journal of respiratory and critical care medicine · 2019
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lisa R Young1 Department of Pediatrics, Medicine, and Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.
Bruce C Trapnell2 Department of Medicine, and.
Kenneth D Mandl4 Department of Pediatrics, and.
Daniel T Swarr6 Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Jennifer A Wambach7 Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; and.
Carol J Blaisdell8 Division of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Funding

Pulmonary Macrophage Transplantation for Pulmonary Alveolar ProteinosisR01HL118342 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI TRAPNELL, BRUCE C, TRAPNELL, BRUCE COLSTON · 2014 to 2021
$4.5M
RLDC: Molecular Pathway-Driven Diagnostics & Therapeutics for Rare Lung DiseasesU54HL127672 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI TRAPNELL, BRUCE C · 2014 to 2018
$3.7M
Mechanisms of Pulmonary Fibrosis in Hermansky-Pudlak SyndromeR01HL119503 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI YOUNG, LISA R. · 2013 to 2021
$3.6M
The role of the long non-coding RNA Falcor in early endoderm and lung developmentK08HL130666 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI SWARR, DANIEL, T (MD) TODD · 2016 to 2020
$807k
NHLBI NIH HHS K08 HL130666NHLBI NIH HHS R01 HL118342NHLBI NIH HHS R01 HL119503NHLBI NIH HHS U54 HL127672
6 · The paper itself

Abstract

Pediatric rare lung disease (PRLD) is a term that refers to a heterogeneous group of rare disorders in children. In recent years, this field has experienced significant progress marked by scientific discoveries, multicenter and interdisciplinary collaborations, and efforts of patient advocates. Although genetic mechanisms underlie many PRLDs, pathogenesis remains uncertain for many of these disorders. Furthermore, epidemiology and natural history are insufficiently defined, and therapies are limited. To develop strategies to accelerate scientific advancement for PRLD research, the NHLBI of the National Institutes of Health convened a strategic planning workshop on September 3 and 4, 2015. The workshop brought together a group of scientific experts, intramural and extramural investigators, and advocacy groups with the following objectives: (1) to discuss the current state of PRLD research; (2) to identify scientific gaps and barriers to increasing research and improving outcomes for PRLDs; (3) to identify technologies, tools, and reagents that could be leveraged to accelerate advancement of research in this field; and (4) to develop priorities for research aimed at improving patient outcomes and quality of life. This report summarizes the workshop discussion and provides specific recommendations to guide future research in PRLD.

Indexed as

Biomedical ResearchChildHumansLung DiseasesNational Heart, Lung, and Blood Institute (U.S.)PediatricsPractice Guidelines as TopicQuality of LifeRare DiseasesUnited Stateschildrendiscoverygenomicsoutcomesrare disease

Identifiers

PMID27925785
PMCPMC5291498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.